Results of a phase 111, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma
1998

Megestrol Acetate and Drug Resistance in Small-Cell Lung Cancer

Sample size: 130 publication Evidence: low

Author Information

Author(s): L Wood, M Palmer, J Hewitt, R Urtasun, E Bruera, E Rapp, JF Thaell

Primary Institution: Cross Cancer Institute

Hypothesis

Does the addition of megestrol acetate to first-line cytotoxic therapy improve survival in small-cell lung cancer patients?

Conclusion

The addition of megestrol acetate did not improve median overall survival or time to disease progression in small-cell lung cancer patients.

Supporting Evidence

  • The median time to disease progression was similar between the megestrol acetate and placebo groups.
  • The median overall survival was not statistically different between the two treatment arms.
  • Response rates did not show significant differences between the megestrol acetate and placebo groups.

Takeaway

The study tested if a drug called megestrol acetate could help cancer patients live longer, but it didn't make a difference.

Methodology

A double-blind, randomized placebo-controlled trial with 130 patients receiving either megestrol acetate or placebo alongside standard chemotherapy.

Limitations

P-glycoprotein levels were not measured at key points, limiting the ability to assess the drug's effect on drug resistance.

Participant Demographics

52% of patients had limited disease and 48% had advanced disease; mean age was around 60 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication